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Abstract
Background: Accuracy of the FreeStyle Libre Flash Glucose Monitoring System has not been evaluated in
pregnant women with diabetes. The aim of this study was to determine accuracy (compared to self-monitoring
of blood glucose [SMBG]), clinical safety, and acceptability of the FreeStyle Libre System when used at home
by this population.
Materials and Methods: Seventy-four participants, with type 1 (T1D, n=24), type 2 (T2D, n=11), or gestational
(n=39) diabetes, were enrolled across 13 sites (9 in United Kingdom, 4 in Austria). Average gestation was 26.6–6.8
weeks (mean– standard deviation), age was 30.5–5.1 years, diabetes duration was 13.1–7.3 years for T1D and
3.2–2.5 years for T2D, and 49/74 (66.2%) used insulin to manage their diabetes. Sensors were worn for up to
14 days. Sensor glucose values (masked) were compared with capillary SMBG values (made at least 4 times/day).
Results: Clinical accuracy of sensor results versus SMBG results was demonstrated, with 88.1% and 99.8% of
results within Zone A and Zones A and B of the Consensus Error Grid, respectively. Overall mean absolute
relative difference was 11.8%. Sensor accuracy was unaffected by the type of diabetes, the stage of pregnancy,
whether insulin was used, age or body mass index. User questionnaires indicated high levels of satisfaction with
sensor wear, system use, and comparison to SMBG. There were no unanticipated device-related adverse events.
Conclusions: Good agreement was demonstrated between the FreeStyle Libre System and SMBG. Accuracy of
the system was unaffected by patient characteristics, indicating that the system is safe and accurate to use by
pregnant women with diabetes.
Keywords: Diabetes, Flash glucose monitoring, Sensor, Pregnancy, Accuracy.
Introduction
The increased risks to both mother and developing fetusimposed on pregnancies complicated by diabetes are
well established.1–3 The risks increase proportionately with
worsening glycemic control.4,5 Effective glucose monitoring
and therapy adjustments are recommended to protect against
diabetes related pregnancy complications.6 Consequently,
the glucose targets during pregnancy are more stringent than
at other times and may predispose women to hypoglycemia.
However, the condition of pregnancy also profoundly affects
glycemic control and the management of diabetes—with
increased glucose variability early in the pregnancy; pro-
gressively increasing insulin resistance, requiring intensifi-
cation of therapy to maintain glucose targets; and increased
risk of hypoglycemia (particularly during the first half of the
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pregnancy7,8), with more rapid onset of insulin-induced
hypoglycemia.2,9 The risk of severe hypoglycemia is a ma-
jor barrier to maintaining strict glycemic control, occurring
up to five times more frequently during early pregnancy
than in the period before pregnancy in women with type 1
diabetes (T1D).10,11 Women with gestational diabetes mellitus
(GDM) have a particular challenge, since they are required to
understand the disease, methods to monitor and control blood
glucose, and the effects of diet, exercise, and medication on
their glucose; all within a very short time frame to optimize
their glucose control quickly through the rest of their preg-
nancy and minimize complications.
The National Institute for Health and Care Excellence
(NICE) recommends that blood glucose levels are tested four
to eight times daily to help achieve glucose targets; with more
frequent testing for patients on an intensive insulin regimen
and less frequent testing for patients on diet and exercise
therapy, oral therapy, or single dose intermediate or long-
acting insulin.1 Self-monitoring of blood glucose (SMBG) is
commonly used for blood glucose monitoring during preg-
nancy and these test rates may be challenging to sustain
throughout a pregnancy. In addition, the glucose variability
and transient glucose excursions that may be experienced
during pregnancy are not easily detectable using SMBG.
Continuous glucose monitoring (CGM) and other glucose
sensor systems collect data at regular/short intervals, pro-
viding a fuller picture of the patient’s glucose profile, rather
than the discrete snap shots obtained from SMBG, without
the pain and inconvenience of regular finger pricking.
CGM is now widely recognized to provide improved clin-
ical outcomes, such as reduced HbA1c, reduced time in
hypoglycemia and hyperglycemia, and increased time in
range, in nonpregnant adults with T1D and type 2 diabetes
(T2D).12–14 However, the evidence to support the use and/
or benefits of continuous sensing technology during preg-
nancy is more limited, and the published studies have re-
ported mixed results on clinical outcomes for both mother
and baby.10,15–18 Reported barriers to CGM use include
technical challenges, calibration, skin irritation, frequent
alarms (especially during sleep), differences between sen-
sor and SMBG measurements, and cost.10,17,19 Despite the
positive outcomes in the recent Continuous Glucose Mon-
itoring in Pregnant Women with Type 1 Diabetes (CON-
CEPTT) study, more than 80% of the women experienced
frustrations with CGM, such as connectivity issues, alarms,
and calibration errors, and 48% of participants experienced
skin reactions following sensor use.20 With the limited evi-
dence of improved clinical outcomes, combined with the
lack of published accuracy data for continuous sensing dur-
ing pregnancy and the high cost of such systems, use of
continuous glucose sensing is generally underutilized in the
pregnant population.
The FreeStyle Libre Flash Glucose Monitoring System
(Abbott Diabetes Care) is designed to replace SMBG testing
for self-management of diabetes (except during rapidly
changing glucose, to confirm hypoglycemia, or if symptoms
do not match sensor results); it provides comprehensive
glucose data (by measuring glucose in interstitial fluid [ISF],
similar to CGM systems) and can be worn for up to 14 days,
without the need for user (finger prick) calibration. The
reader displays the glucose results after scanning over the
small sensor worn on the back of the arm; it has no automatic
alarms, but can alert the user to hypoglycemia or hypergly-
cemia and projected excursions when detected following a
scan. At the time of the study, the system was approved for
use in adults (with a limitation on use during pregnancy) and
children. The aim of this study was to evaluate accuracy,
safety, and user acceptability of the FreeStyle Libre Flash
Glucose Monitoring System when used by pregnant women
with diabetes.
Materials and Methods
This prospective single arm study was conducted across
13 diabetes centers in the United Kingdom and Austria. The
study (NCT02665455) was conducted in compliance with
the study protocol and International Conference on Har-
monisation Guideline for Good Clinical Practice. Compe-
tent Authority approval (Medicines and Healthcare Products
Regulatory Agency [MHRA] and Bundesamt fu¨r Sicherheit
in Gesundheitswesen [BASG]) and Ethics Committee ap-
provals (including the Health Research Authority within
United Kingdom) were obtained, and each participant gave
written informed consent before participation in the study.
Study participants
Women aged ‡18 years at ‡12 weeks gestation with a
singleton pregnancy, with T1D, T2D, or GDM, and testing
blood glucose at least twice per day were eligible to partici-
pate in the study. Exclusion criteria included concomitant
disease or condition that may compromise patient safety;
currently receiving or planning to receive dialysis treatment
during the study, or moderate to advanced nephropathy; di-
abetic ketoacidosis in the previous 6 months; known or sus-
pected allergy to medical grade adhesives; and experience of
preeclampsia, HELLP (hemolysis, elevated liver enzymes,
and low platelet count) syndrome, or prescribed tocolytic
drugs for treatment of preterm labor during the current
pregnancy. Any potentially eligible patient from the general
diabetes population at each study site was invited to partici-
pate.
Study design
There were three scheduled in-clinic visits. Visit 1 in-
cluded data collection on demographics, current glucose
management methods, prepregnancy glucose management
methods (for participants with T1D or T2D), prepregnancy
weight and HbA1c, previous pregnancies, and lifestyle;
provision of a blood sample for HbA1c, fructosamine, and
hematocrit measurement; height, weight, and blood pres-
sure measurement; and sensor insertion and sensor appli-
cation questionnaire. No device training was provided,
other than instructions on how to use the device in masked
mode and the product labeling. Adverse events (AEs) were
reviewed at every participant contact.
Participants wore the sensor (on the back of their upper
arm) for up to 14 days. Throughout this period, participants
were asked to perform at least four premeal capillary blood
glucose (SMBG) tests daily using the blood glucose strip-port
on the reader (and FreeStyle Optium test strips; Abbott
Diabetes Care), each immediately followed by an ISF glu-
cose sensor measurement (data masked to participants) to
allow comparison of results between sensor and SMBG.
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At clinic visit 2 (between days 5 and 8) data from the
device were uploaded, frequency of SMBG tests was re-
viewed, and any AEs experienced or concomitant medication
changes were recorded.
During the final clinic visit (between days 12 and 15), the
reader was unmasked for participants to experience full
functionality of the system (for a short time while in-clinic),
sensors were removed, data were uploaded, a blood sample
was provided for HbA1c, fructosamine, and hematocrit
measurement, user questionnaires were completed by the
participant, and any AEs or concomitant medication changes
were recorded.
Three sensor lots were used through the study, rotated
within each study site, one lot per participant.
Participants were asked to maintain their preexisting dia-
betes management plan throughout their involvement in the
study.
Statistical analysis
Sensor values were compared with all temporally matched
(within –5 min) capillary blood glucose values, including
those made in addition to the four premeal tests. The primary
accuracy end point was the percentage of sensor results
within Zone A of the Consensus Error Grid (ConEG) com-
pared to SMBG results. A minimum sample size of 64 par-
ticipants was required to detect a ‡5% difference in the mean
percentage of paired points within Zone A of the ConEG,
with a significance level of 5% and a power of 80%.
Other accuracy end points included ConEG and Clarke
Error Grid analysis to evaluate the clinical accuracy of the
system. Mean absolute relative difference (MARD), median
absolute relative difference (median ARD), mean absolute
difference (MAD), and mean relative difference (MRD)
were used to evaluate analytical accuracy of the system.
MAD and MARD were used to evaluate accuracy at low
(<5.6 mmol/L [100 mg/dL]) and mid-to-high (‡5.6 mmol/L)
glucose ranges, respectively. The proportion of results within
–1.1 mmol/L (20 mg/dL) of the SMBG value for glucose
levels <5.6 mmol/L and within –20% of the SMBG value for
glucose levels ‡5.6 mmol/L (% within 1.1/20) was also used
to evaluate overall analytical accuracy of the system. Mul-
tiway analysis of variance (ANOVA) was used to assess
whether a range of factors affected sensor accuracy.
End points also included glycemic variability, where time
in range, number and duration of hypoglycemic and hyper-
glycemic events, mean glucose, and standard deviation [SD]
glucose were each determined for the overall study popula-
tion and by the type of diabetes and diabetes management
method. Time in range was defined for two separate analyses,
as glucose results in the ranges 3.9–10.0 mmol/L (70–
180 mg/dL) and 3.9–7.8 mmol/L (70–140 mg/dL), the tighter
range aligning with NICE glucose targets for pregnant wo-
men 1 h after meals.1 A hypoglycemic event was defined for
two separate analyses as excursions of at least 15 min below
the target range (<3.9 mmol/L [70 mg/dL] and <3.0 mmol/L
[54 mg/dL]), and a hyperglycemic event was defined for two
separate analyses as excursions of at least 15 min above the
target range (>10.0 mmol/L [180 mg/dL] and >7.8 mmol/L
[140 mg/dL]).
Safety outcomes were analyzed for all enrolled partici-
pants, whether a sensor was worn or not.
All analyses were performed using SAS software, version
9.2 or later (SAS Institute, Cary, NC). Missing data were not
imputed in the statistical analysis.
Results
Eighty-three participants were enrolled in the study. Nine
participants withdrew from the study on or before visit 1 and
before sensor application: five participants chose to withdraw
from the study (too busy or changed their mind); a further
four participants were withdrawn by the investigator for a
number of reasons (e.g., no longer met the inclusion/exclu-
sion criteria, such as diagnosis of preeclampsia); no with-
drawals were associated with use of the device. Therefore, 74
evaluable participants were included in the accuracy and
glycemic variability analyses; all 83 participants were in-
cluded in the safety analysis. Of the 74 evaluable participants,
49 (66.2%) were on insulin therapy, 18 (24.3%) were on diet
only, and 7 (9.5%) were on metformin only; 39 (52.7%) had
GDM, 24 (32.4%) had T1D, and 11 (14.9%) had T2D; and 29
(39.2%) were in the second trimester and 45 (60.8%) were in
the third trimester of pregnancy. Of the participants on insulin
Table 1. Baseline Characteristics
of Study Participants
Characteristic
Diabetes
type Mean – SD Median Range N
Age (years) Gestational 31.0 – 4.9 31.0 21–41 39
Type 1 28.4 – 5.2 29.0 19–37 24
Type 2 33.4 – 3.7 33.0 27–39 11
Overall 30.5 – 5.1 31.0 19–41 74
Body mass
index
(kg/m2)
Gestational 34.2 – 6.8 33.2 20.8–48.2 39
Type 1 27.8 – 4.5 27.7 19.5–35.1 24
Type 2 35.9 – 8.4 33.8 23.7–50.4 11
Overall 32.4 – 7.1 31.7 19.5–50.4 74
HbA1c
(mmol/mol)
Gestational 35.3 – 4.8 35.0 27–49 38a
Type 1 48.3 – 8.7 48.0 28–68 24
Type 2 39.3 – 8.5 39.0 31–61 11
Overall 40.2 – 9.0 38.0 27–68 73a
HbA1c (%) Gestational 5.4 – 0.4 5.4 4.6–6.6 38a
Type 1 6.6 – 0.8 6.5 4.7–8.4 24
Type 2 5.7 – 0.8 5.7 5.0–7.7 11
Overall 5.8 – 0.8 5.6 4.6–8.4 73a
Fructosamine
(lmol/L)
Gestational 203 – 17 198 171–249 38a
Type 1 260 – 48 255 198–380 24
Type 2 212 – 28 210 175–260 11
Overall 223 – 41 210 171–380 73a
Hematocrit (%) Gestational 35.2 – 2.3 35.8 29.6–39.1 38a
Type 1 36.7 – 2.9 36.2 32.4–43.7 24
Type 2 36.5 – 3.1 37.2 32.5–40.6 11
Overall 35.9 – 2.7 35.9 29.6–43.7 73a
Gestation
(weeks)
Gestational 28.9 – 5.2 29.0 14–36 39
Type 1 25.2 – 6.9 26.0 13–35 24
Type 2 21.6 – 8.7 18.0 13–35 11
Overall 26.6 – 6.8 28.0 13–36 74
Duration of
diabetes
(years)
Gestational 0.1 – 0.1 0.1 0.0–0.5 39
Type 1 13.1 – 7.3 13.0 0.3–24.8 24
Type 2 3.2 – 2.5 3.4 0.2–8.3 11
Overall 4.8 – 7.3 0.3 0–24.8 74
BG tests/day
(self-
reported)
Gestational 4.7 – 1.1 4.0 4–7 39
Type 1 7.9 – 1.8 7.5 5–12 24
Type 2 4.8 – 1.1 4.0 4–7 11
Overall 5.7 – 2.0 5.0 4–12 74
aOne participant with gestational diabetes does not have baseline
laboratory results, since they were unable to provide a blood sample
during visit 1.
SD, standard deviation.
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therapy, 15 had GDM, 24 had T1D, and 10 had T2D. At
baseline, participants’ average age was 30.5–5.1 years
(mean–SD), HbA1c was 40.2–9.0 mmol/mol (5.8%–0.8%),
fructosamine 223– 41lmol/L, and hematocrit was 35.9%–
2.7%. Other characteristics of the evaluable study participants,
including a breakdown by diabetes type, are included in
Table 1 (nonevaluable participants withdrew from the study
before collection of demographic data).
There were 5031 paired capillary blood glucose to sensor
glucose values used in the accuracy analyses. ConEG anal-
ysis demonstrated 88.1% of results in Zone A and 99.8% of
results in Zones A and B (Fig. 1A) of the error grid. Clarke
Error Grid analysis demonstrated 83.6% of results in Zone A
and 99.1% of results in Zones A and B (Fig. 1B) of the error
grid. Deming regression determined a slope of 1.12 and an
intercept of -0.84 mmol/L (-15.1 mg/dL), with a correlation
coefficient of 0.92. The overall MARD was 11.8%, median
ARD was 9.5%, MRD was -1.1%, and the % within 1.1/20
was 87.1%. For paired results at lower glucose concentrations,
with blood glucose <5.6 mmol/L (100 mg/dL) (n = 2133),
MAD was 0.53 mmol/L (9.6 mg/dL); for those at higher
glucose concentrations, with blood glucose ‡5.6 mmol/L
(‡100 mg/dL) (n = 2898), MARD was 11.7%.
Accuracy of the system was the same with and without
the rapidly changing glucose results included in the analysis
(Table2), indicating that the accuracy remains stable during times
of rapidly changing glucose, such as in the postprandial state.
The accuracy was similar across the subgroups, with a
similar percentage of results in Zone A and in Zones A and B
of the ConEG (Table 2)—there were no statistically
FIG. 1. Consensus (A) and Clarke (B) error grid analysis comparing FreeStyle Libre sensor results to capillary BG results.
BG, blood glucose.
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significant differences (at a 5% level) in accuracy detected
(ANOVA) for diabetes type, insulin versus noninsulin users,
trimester, age group, body mass index (BMI), or sensor lot.
Glycemic variability of participants during their time in the
study was determined from sensor data collected during the
study. Duration within different glucose ranges and number
of hypoglycemic and hyperglycemic events are broken down
by diabetes type and insulin use (Table 3). As may be expected,
time in range was lower for insulin using participants than
noninsulin using participants and lower for participants with
T1D than those with GDM and T2D; these were driven by the
higher mean glucose for participants using insulin or with T1D.
Study participants completed a questionnaire (visits 1 and
3) and rated their experience with the system on a scale of 1
(strongly agree/painless) to 5 (strongly disagree/severe pain).
Statements about sensor application (88.9%–95.8%), sensor
wear and use (55.4%–100.0%), and comparisons to SMBG
(93.7%–100.0%) were rated favorably (strongly agree/pain-
less or agree/almost painless) by most participants (Fig. 2).
There were 27 AEs reported by 23 participants, none of
which were related to the study device or study procedure.
Of the 27 AEs, 4 were serious AEs (suspected preeclampsia,
preeclampsia, vomiting, and decreased fetal movement).
There were no unanticipated device related AEs. Five (6.8%)
of the 74 participants reported experiencing 11 signs or
symptoms associated with sensor application or insertion
sites (bleeding, bruising, erythema, itching, and pain); all
were mild in severity and resolved at study completion.
Discussion
This study evaluated the performance and usability of the
FreeStyle Libre System in pregnant women and is one of few
glucose sensor accuracy studies for this population reported
in the literature.21,22 The infrequent reporting of sensor ac-
curacy studies involving pregnant women may be a result of
few CGM systems being approved for use during pregnancy
and some systems having a contraindication for use during
pregnancy. At the time of the study, the FreeStyle Libre
System had a similar contraindication. The study results
demonstrated good agreement between the sensor glucose
values and capillary blood glucose values, as illustrated
through the different statistical and clinical accuracy mea-
sures reported, with comparable accuracy to that reported in
the nonpregnant population.23 In a study of 72 adults with
T1D and T2D using the FreeStyle Libre System, MARD
was 11.4%, the percentage of results in Zone A and in Zones
A and B combined of the ConEG was 86.7% and 99.7%,
respectively, all compared to capillary blood glucose mea-
surements. Use of capillary blood glucose as reference results
Table 2. Consensus Error Grid Analysis of Subgroup
Subgroup
Consensus zone
Total
N
A A and B B C D E
N % P N % P N % N % N % N %
Rapidly changing
All results 4433 88.1 N/Aa 5022 99.8 N/Aa 589 11.7 9 0.2 0 0.0 0 0.0 5031
Excluding results during
rapidly changing glucose
4215 88.6 4752 99.8 537 11.3 8 0.2 0 0.0 0 0.0 4760
Diabetes type
Gestational 2328 89.4 0.2985 2603 100.0 0.6128 275 10.6 1 0.0 0 0.0 0 0.0 2604
Type 1 1461 85.4 1704 99.6 243 14.2 6 0.4 0 0.0 0 0.0 1710
Type 2 644 89.8 715 99.7 71 9.9 2 0.3 0 0.0 0 0.0 717
Insulin use
Insulin 2751 86.6 0.2351 3166 99.7 0.0702 415 13.1 9 0.3 0 0.0 0 0.0 3175
Noninsulin 1682 90.6 1856 100.0 174 9.4 0 0.0 0 0.0 0 0.0 1856
Trimester
Second 1602 87.1 0.2723 1836 99.8 0.8504 234 12.7 4 0.2 0 0.0 0 0.0 1840
Third 2831 88.7 3186 99.8 355 11.1 5 0.2 0 0.0 0 0.0 3191
Age (years)
<25 477 86.7 0.7625 549 99.8 0.7226 72 13.1 1 0.2 0 0.0 0 0.0 550
25–30 1503 86.8 1730 99.9 227 13.1 2 0.1 0 0.0 0 0.0 1732
31–35 1646 88.7 1852 99.8 206 11.1 3 0.2 0 0.0 0 0.0 1855
>35 807 90.3 891 99.7 84 9.4 3 0.3 0 0.0 0 0.0 894
Body mass index (kg/m2)
<25 621 88.6 0.2770 699 99.7 0.2224 78 11.1 2 0.3 0 0.0 0 0.0 701
‡25 and <30 1268 88.5 1432 99.9 164 11.4 1 0.1 0 0.0 0 0.0 1433
‡30 and £35 1336 88.2 1512 99.8 176 11.6 3 0.2 0 0.0 0 0.0 1515
>35 1208 87.4 1379 99.8 171 12.4 3 0.2 0 0.0 0 0.0 1382
Sensor lot
A 1439 88.6 0.1129 1622 99.8 0.1954 183 11.3 3 0.2 0 0.0 0 0.0 1625
B 1539 85.7 1794 99.9 255 14.2 1 0.1 0 0.0 0 0.0 1795
C 1455 90.3 1606 99.7 151 9.4 5 0.3 0 0.0 0 0.0 1611
aBetween-group comparison not performed since the set excluding results during rapidly changing glucose is a subset of all results.
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allowed evaluation of real-life accuracy of the system under
normal daily use, which would include fasting and post-
prandial periods around meals, impact of medication (in-
cluding insulin), and sedentary and more active periods.
This study has also confirmed that sensor accuracy is robust
to patient characteristics such as age, BMI, insulin versus
noninsulin use, diabetes type, and also to the stage of preg-
nancy. Similar observations about the system being robust to
a number of patient variables have been made in other studies
using the FreeStyle Libre System in nonpregnant partici-
pants.23,24 Accuracy of the FreeStyle Libre System, in com-
bination with its robustness to differing patient characteristics,
is sufficient to recommend its use to pregnant patients as
support in optimizing their glycemic control and achieving the
tight glucose control needed during pregnancy.
The system is unique among current glucose sensing
technology options in that it does not require user calibration
and it can be worn for up to 14 days. There are limited
published data to allow comparison of the accuracy of the
FreeStyle Libre System in this study to that for other con-
tinuous glucose sensors. However, the relationship between
average glucose and HbA1c is similar to that reported for
pregnant women with T1D and T2D using conventional
CGM.25 One study reported accuracy of the FreeStyle Nav-
igator CGM during exercise for pregnant subjects with T1D,
with a median ARD of 11.8% and 96% of results within
Zones A and B of the Clarke Error Grid at rest compared to
venous blood glucose results (352 paired sensor-blood glu-
cose results).21 Accuracy was lower during exercise. Another
study in pregnant women with T1D also reported on the ac-
curacy of the Freestyle Navigator CGM,22 with MARD and
median ARD of 13.3% and 11.4% (n= 1923), respectively,
compared to venous plasma glucose. Although the two
studies were very different in design to the current study, the
Table 3. Time in Key Glycemic Ranges and Laboratory Parameters at Final Study Visit
Type of diabetes Insulin use
Overall Gestational Type 1 Type 2 Insulin Noninsulin
n (participants) 74 39 24 11 49 25
Sensor glucose
Mean (SD) mmol/L 6.17 (1.65) 5.39 (0.85) 7.63 (1.97) 5.76 (0.71) 6.60 (1.81) 5.32 (0.77)
mg/dL 111.1 (29.7) 97.1 (15.3) 137.4 (35.5) 103.7 (12.7) 118.9 (32.6) 95.9 (13.9)
Time in range, hypoglycemia, and hyperglycemia, hours/day (24 h)
3.9–10.0 mmol/L
[70–180 mg/dL]
mean (SD) 18.9 (4.2) 20.6 (3.5) 15.6 (4.0) 19.9 (2.6) 17.6 (4.2) 21.4 (2.8)
3.9–7.8 mmol/L
[70–140 mg/dL]
mean (SD) 16.4 (5.1) 19.1 (3.9) 11.6 (4.1) 17.4 (3.4) 14.4 (4.8) 20.3 (3.3)
<3.9 mmol/L
[<70 mg/dL]
mean (SD) 3.26 (3.08) 3.12 (3.57) 3.43 (2.52) 3.36 (2.44) 3.69 (3.13) 2.42 (2.86)
<3.0 mmol/L
[<54 mg/dL]
mean (SD) 1.06 (1.49) 0.79 (1.39) 1.51 (1.82) 1.02 (0.78) 1.38 (1.71) 0.44 (0.57)
>10.0 mmol/L
[>180 mg/dL]
mean (SD) 1.88 (3.29) 0.30 (0.76) 4.98 (4.24) 0.73 (1.00) 2.75 (3.74) 0.18 (0.57)
>7.8 mmol/L
[>140 mg/dL]
mean (SD) 4.33 (4.86) 1.75 (2.85) 9.00 (4.90) 3.29 (2.68) 5.90 (5.01) 1.26 (2.62)
Frequency of hypoglycemic and hyperglycemic events/day (24 h)
<3.9 mmol/L
[<70 mg/dL]
mean (SD) 1.86 (1.20) 1.75 (1.31) 2.01 (1.02) 1.94 (1.24) 2.06 (1.19) 1.48 (1.16)
<3.0 mmol/L
[<54 mg/dL]
mean (SD) 0.69 (0.71) 0.54 (0.69) 0.91 (0.76) 0.73 (0.58) 0.87 (0.78) 0.33 (0.36)
>10.0 mmol/L
[>180 mg/dL]
mean (SD) 0.80 (1.03) 0.23 (0.50) 1.79 (1.07) 0.64 (0.71) 1.13 (1.10) 0.14 (0.38)
>7.8 mmol/L
[>140 mg/dL]
mean (SD) 1.81 (1.24) 1.22 (1.18) 2.62 (0.95) 2.11 (0.92) 2.26 (1.08) 0.93 (1.07)
Overall glucose variability
Standard deviation mmol/L 1.91 (1.09) 1.26 (0.33) 3.06 (1.17) 1.69 (0.37) 2.32 (1.13) 1.11 (0.20)
mg/dL 34.4 (19.6) 22.7 (6.0) 55.2 (21.2) 30.5 (6.6) 41.7 (20.4) 20.1 (3.6)
Coefficient of variation, % 29.5 (9.2) 23.4 (4.8) 39.3 (7.4) 29.5 (5.3) 33.8 (8.2) 21.0 (2.7)
Laboratory parameters at final study visita
n (participants) 73H, 72F 38H, 37F 24H,F 11H,F 49H,F 24H, 23F
HbA1c mmol/mol 40 36 48 39 43 34
% 5.8 5.4 6.5 5.7 6.1 5.2
Fructosamine (lmol/L) 217 198 252 202 225 199
Hematocrit (%) 35.4 35.1 35.9 35.2 35.5 35.1
aOnly participants with laboratory parameters obtained at both baseline and visit 3 are included. One participant did not have baseline
laboratory results (refer to Table 1). One participant did not have a fructosamine result for visit 3, since the laboratory was unable to analyze
results: Hn for HbA1c and Hematocrit, Fn for Fructosamine.
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results provide an indication that the accuracy of the factory
calibrated FreeStyle Libre System (99.1% of results within
Zones A and B of Clarke Error Grid, MARD 11.8%, and
median ARD 9.5% for overall population) compares well
with that for CGM systems requiring user (finger prick)
calibration. As noted in other publications, the lack of user
calibration eliminates potential variations in sensor systems
that may be introduced through errors in SMBG results used
for calibration, calibration at inappropriate times (during rap-
idly changing glucose), missing calibrations, or use of sensor
glucose rather than SMBG values for calibration.23,24,26–28
The masked sensor data collected throughout the study
provided a snapshot of the time the participants from the
United Kingdom and Austria spent in key glycemic ranges
during their 2 weeks in the study, throughout which the
participants were using SMBG to manage their diabetes.
NICE recommends that patients on insulin are advised to
maintain blood glucose levels >4 mmol/L (72 mg/dL).1 The
insulin using participants in this study were not meeting this
glucose target, with glucose levels <3.9 mmol/L (70 mg/dL)
for 3.7 h per day. Other glucose targets recommended by
NICE relate to fasting (<5.3 mmol/L [95 mg/dL]) and post-
meal targets (<7.8 mmol/L [140 mg/dL] 1 h after meals or
<6.4 mmol/L [115 mg/dL] 2 h after meals) and apply equally
to patients with T1D, T2D, and GDM.1 While these aren’t
specifically evaluated in this study, the time participants
spent with glucose >7.8 mmol/L (140 mg/dL) was 4.3 h per
day on average for the full study population and as high as
9.0 h per day on average for the T1D subgroup and 5.9 h per
day on average for the insulin using subgroup, suggesting that
postmeal targets were also not being met. Although these data
only represent a 2-week period, it suggests that there is sig-
nificant opportunity to improve glycemic control in pregnant
women with diabetes.
SMBG provides single, intermittent glucose values, which
may not capture transient glucose excursions caused by the
increased glucose variability experienced during pregnancy. In
comparison, the FreeStyle Libre System displays the current
glucose value, the last 8 h of glucose data, and trend information
each time the sensor is scanned; providing significantly more
data to guide treatment decisions for this challenging population
than SMBG. While the system does not provide automated
alarms for hypoglycemia and hyperglycemia, it does provide
screen alerts when hypoglycemia and hyperglycemia are de-
tected, or when glucose is projected to be hypoglycemic or
hyperglycemic within 15 min, following a scan. Other studies
have demonstrated that use of the FreeStyle Libre System can
significantly reduce the amount of time spent in hypoglyce-
mia.13,14 Further studies are needed to confirm whether the same
improvement can be achieved with its use during pregnancy.
FIG. 2. User acceptability questionnaire results.
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The study has demonstrated safety and user acceptability
of the FreeStyle Libre System among a pregnant population.
Similar to a study performed in nonpregnant adults, there
were no unanticipated device related AEs.23 Anticipated
signs or symptoms associated with sensor application or in-
sertion sites (bleeding, bruising, erythema, itching, and pain)
were reported for 7% of participants, a lower rate than ob-
served in previous studies where nonpregnant adults (36%)
and children and young people (44%) used the system.23,24
The user experience questions were rated favorably by most
participants following sensor application, sensor wear and use,
and in comparison to SMBG testing. Other studies have asso-
ciated lack of improvement in glycemic control to reduced
sensor wear and poor adherence to CGM.29–33 The high user
acceptability demonstrated in this study (and in other studies
following extended use of the FreeStyle Libre System13,14), to-
gether with the simplicity of the system and absence of alarms,
may imply higher user compliance when using this system than
has been observed in CGM studies in pregnancy.10,15,18,19
Limitations of this study are that the study design was not
powered to compare accuracy between different subgroups
and that a mixed cohort was used. Longer term studies, using
the full functionality of the system (unmasked), are required
to evaluate whether this system can provide improved ad-
herence with sensor wear and improved glycemic and preg-
nancy outcomes for mother and baby. Such studies could
evaluate women with different types of diabetes separately to
determine whether improvements in glycemic control and
pregnancy outcomes can be achieved in T2D and GDM in
addition to T1D.
Conclusions
The accuracy, safety, and user acceptability of the Free-
Style Libre System for women with diabetes during preg-
nancy have been demonstrated. Accuracy was unaffected by
the type of diabetes (T1D, T2D, GDM), whether or not in-
sulin was used, the stage of pregnancy, the age or BMI of the
participants, thus making the system suitable for women with
diabetes during pregnancy. It is anticipated that the provision
of comprehensive glucose data for up to 14 days, from a
system that is easy to use, could support enhanced diabetes
management during pregnancy. In addition, the reduced pain
and burden for the user (since finger-stick calibration is not
required) and lack of alarms may support more extensive use
of glucose sensing, since these were two of the barriers to
more extensive CGM use reported in previous studies
evaluating CGM use during pregnancy. Further studies are
needed to investigate whether improved glycemic control
and pregnancy outcomes for the mother and baby can be
achieved with prolonged use of the FreeStyle Libre System
during pregnancy.
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